Toxicokinetic modeling of folpet fungicide and its ring-biomarkers of exposure in humans
Article first published online: 19 DEC 2011
Copyright © 2011 John Wiley & Sons, Ltd.
Journal of Applied Toxicology
Volume 33, Issue 7, pages 607–617, July 2013
How to Cite
Heredia-Ortiz, R., Berthet, A. and Bouchard, M. (2013), Toxicokinetic modeling of folpet fungicide and its ring-biomarkers of exposure in humans. J. Appl. Toxicol., 33: 607–617. doi: 10.1002/jat.1782
- Issue published online: 23 MAY 2013
- Article first published online: 19 DEC 2011
- Manuscript Accepted: 7 NOV 2011
- Manuscript Revised: 3 NOV 2011
- Manuscript Received: 29 SEP 2011
A human in vivo toxicokinetic model was built to allow a better understanding of the toxicokinetics of folpet fungicide and its key ring biomarkers of exposure: phthalimide (PI), phthalamic acid (PAA) and phthalic acid (PA). Both PI and the sum of ring metabolites, expressed as PA equivalents (PAeq), may be used as biomarkers of exposure. The conceptual representation of the model was based on the analysis of the time course of these biomarkers in volunteers orally and dermally exposed to folpet. In the model, compartments were also used to represent the body burden of folpet and experimentally relevant PI, PAA and PA ring metabolites in blood and in key tissues as well as in excreta, hence urinary and feces. The time evolution of these biomarkers in each compartment of the model was then mathematically described by a system of coupled differential equations. The mathematical parameters of the model were then determined from best fits to the time courses of PI and PAeq in blood and urine of five volunteers administered orally 1 mg kg−1 and dermally 10 mg kg−1 of folpet. In the case of oral administration, the mean elimination half-life of PI from blood (through feces, urine or metabolism) was found to be 39.9 h as compared with 28.0 h for PAeq. In the case of a dermal application, mean elimination half-life of PI and PAeq was estimated to be 34.3 and 29.3 h, respectively. The average final fractions of administered dose recovered in urine as PI over the 0–96 h period were 0.030 and 0.002%, for oral and dermal exposure, respectively. Corresponding values for PAeq were 24.5 and 1.83%, respectively. Finally, the average clearance rate of PI from blood calculated from the oral and dermal data was 0.09 ± 0.03 and 0.13 ± 0.05 ml h−1 while the volume of distribution was 4.30 ± 1.12 and 6.05 ± 2.22 l, respectively. It was not possible to obtain the corresponding values from PAeq data owing to the lack of blood time course data. Copyright © 2011 John Wiley & Sons, Ltd.